Disclosed herein is a method for multimodal imaging during a medical procedure using magnetic resonance imaging (MRI) and Raman optical imaging which involves administering an MRI imaging contrast agent that a chemical structure having charge-transfer electronic transitions. The tissue is imaged using and MRI device and the tissue is illuminated with excitation light that has spectral components that are approximately tuned close to one of the charge-transfer electronic transitions thereby producing enhanced Raman optical signals which are analyzed to produce Raman imaging data followed by registering the MRI and Raman imaging data. The present disclosure also provides a method for ionizing laser plumes through atmospheric pressure chemical ionization.

The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.

A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

The present application is in the field of imaging reagents. In particular, the present application relates to labelled fluorocarbon imaging reagents, the preparation of the reagents, and their uses for imaging such as PET scanning.

The present application is in the field of imaging reagents. In particular, the present application relates to labelled fluorocarbon imaging reagents, the preparation of the reagents, and their uses for imaging such as PET scanning.

In a method (100 to 208) in which hyperpolarizable tracer molecules (20, 88 to 98) are hydrogenated and then optionally also hyperpolarized for magnetic resonance imaging, it is provided that, in a first method step (104, 202), a hydrogen solution (10, 12, 4) having a saturation factor of at least 50% be prepared and that the hydrogenation reaction (186 to 190, 206) not be triggered until a subsequent, second method step (106, 204). An apparatus (1) with which the method of the invention (100 to 208) is executable is also provided.

The present invention relates to a novel gadolinium-based compound having a structure in which a gadolinium complex and ferulic acid are linked via a linker, a preparation method therefor, and an MM contrast agent containing same.

The present invention relates to a novel gadolinium-based compound having a structure in which a gadolinium complex and ferulic acid are linked via a linker, a preparation method therefor, and an MM contrast agent containing same.

A magnetic resonance imaging (MRI) contrast agent and a preparation method and a use thereof is provided, which belong to the technical field of Magnetic Resonance Imaging contrast agent. The MRI contrast agent is prepared by the compound having a structure of formula I; and it also may include the compound having a structure of formula II or a pharmaceutically acceptable salt thereof, wherein M.sub.1 is a divalent ion or a trivalent ion of a paramagnetic metal selected from Mn, Fe, Eu, or Dy; M.sub.2 is selected from Na.sup.+, K.sup.+ or meglumine cation; when M.sub.1 is a divalent ion, a is 2; when M.sub.1 is a trivalent ion, a is 3. The MRI contrast agent has good water solubility, high relaxivity, and low toxic and side effect.

##STR00001##

Systems and methods are provided for producing hyperpolarized materials for use during a magnetic resonance imaging (MRI) or nuclear magnetic resonance (NMR) process. The system and methods include the use of microfluidic and/or microreactor methods in one or more of the stages of parahydrogen production, enriched substrate production, and spin order transfer from the parahydrogen to a substrate.